Atrial Fibrillation

Atrial fibrillation (AF) is a supraventricular tachyarrhythmia characterized by rapid, disorganized electrical activity in the atria, leading to ineffective atrial contraction and an irregularly irregular ventricular response. In veterinary medicine, AF is most commonly recognized in dogs, particularly large and giant breeds, and less frequently in cats. The arrhythmia arises from multiple reentrant wavelets or ectopic foci in the atria, often triggered by atrial enlargement, fibrosis, or autonomic imbalance. AF can be classified as primary (lone AF) when no underlying structural heart disease is present, or secondary when associated with conditions such as mitral valve disease, dilated cardiomyopathy, or hyperthyroidism. The hemodynamic consequences include loss of atrial kick, reduced cardiac output, and increased risk of thromboembolism, though the latter is rare in dogs and cats compared to humans. Clinical presentation varies from asymptomatic to severe congestive heart failure, depending on the ventricular rate and underlying cardiac disease.

The etiology of atrial fibrillation in veterinary patients is multifactorial. In dogs, the most common underlying causes include chronic valvular heart disease (myxomatous mitral valve degeneration), dilated cardiomyopathy (DCM), and congenital heart defects such as patent ductus arteriosus or ventricular septal defect. Lone AF, occurring in the absence of structural heart disease, is seen in large-breed dogs, particularly Irish Wolfhounds, Great Danes, and Boxers, and may have a genetic predisposition. In cats, AF is rare but can occur secondary to hypertrophic cardiomyopathy, hyperthyroidism, or systemic hypertension. Other etiologic factors include electrolyte disturbances (hypokalemia, hypomagnesemia), acid-base imbalances, hypoxia, sepsis, and drug toxicities (e.g., digitalis, sympathomimetics). Autonomic influences, such as increased sympathetic tone or decreased vagal tone, can precipitate AF in susceptible individuals. Inflammatory or infiltrative myocardial diseases, such as myocarditis or cardiac neoplasia, may also serve as triggers. The exact molecular mechanisms involve electrical remodeling (shortening of atrial refractory period) and structural remodeling (atrial fibrosis), which promote reentry.

Atrial fibrillation is the most common clinically significant arrhythmia in dogs, accounting for approximately 5-15% of all canine arrhythmias. It is predominantly seen in large and giant breeds, with a higher prevalence in males and older animals. Breeds at increased risk include Irish Wolfhound, Great Dane, Boxer, Doberman Pinscher, and German Shepherd. In Irish Wolfhounds, AF is often familial and may occur as lone AF in middle-aged dogs. In cats, AF is uncommon, with a prevalence of less than 1% in the general feline population, but it may be seen in cats with severe cardiac disease, particularly those with marked atrial enlargement. The incidence of AF increases with age, correlating with the development of degenerative valvular disease in dogs. No significant geographic or seasonal variation has been reported. In horses, AF is also common, but this entry focuses on small animals.

The pathophysiology of atrial fibrillation involves a complex interplay of electrical and structural remodeling. The initiating event is often a premature atrial contraction that encounters areas of heterogeneous refractoriness, leading to reentry. Once initiated, AF is perpetuated by multiple reentrant wavelets that wander through the atria, facilitated by shortened atrial refractory periods and slowed conduction velocity. Electrical remodeling occurs due to rapid atrial rates, causing downregulation of L-type calcium channels and alterations in potassium currents, which shorten the action potential duration and refractory period. Structural remodeling, including atrial fibrosis and dilation, provides a substrate for reentry. The loss of atrial contraction (atrial kick) reduces ventricular filling by 15-30%, leading to decreased stroke volume and cardiac output. The ventricular response rate is determined by the conduction properties of the atrioventricular (AV) node, which is influenced by autonomic tone. In dogs, the ventricular rate in AF is often rapid (180-300 bpm), leading to diastolic dysfunction, increased myocardial oxygen demand, and potential myocardial ischemia. Chronic tachycardia can result in tachycardia-induced cardiomyopathy, further impairing cardiac function. Additionally, stasis of blood in the atria increases the risk of thrombus formation, although thromboembolism is rare in dogs and cats compared to humans.

Predisposing factors for atrial fibrillation include underlying structural heart disease, particularly conditions that cause atrial enlargement such as chronic mitral valve disease, dilated cardiomyopathy, and congenital shunts. Large and giant breed dogs are inherently predisposed, possibly due to larger atrial mass and longer conduction pathways. Age is a significant factor, as degenerative changes accumulate over time. Electrolyte imbalances, especially hypokalemia and hypomagnesemia, can increase atrial excitability. Hyperthyroidism in cats increases sympathetic tone and can precipitate AF. Obesity and systemic hypertension may contribute to atrial remodeling. Genetic factors are evident in certain breeds, such as Irish Wolfhounds, where AF is inherited as an autosomal dominant trait with variable penetrance. Medications that increase sympathetic activity, such as sympathomimetics or phosphodiesterase inhibitors, can trigger AF. Stress, pain, and hypoxia are acute precipitating factors. In hospitalized patients, sepsis and systemic inflammatory response syndrome can lead to AF.

Clinical signs of atrial fibrillation vary depending on the ventricular rate, duration of arrhythmia, and presence of underlying heart disease. In dogs with well-controlled ventricular rates and no structural heart disease, AF may be an incidental finding on physical examination. When signs are present, they include exercise intolerance, lethargy, weakness, syncope, and dyspnea. In severe cases, signs of congestive heart failure such as coughing, tachypnea, and ascites may develop. On physical examination, the most characteristic finding is an irregularly irregular heart rhythm with a pulse deficit (pulse rate lower than heart rate). Heart sounds may be variable in intensity, and a murmur may be present if underlying valvular disease exists. In cats, signs are often related to the underlying cardiomyopathy and may include respiratory distress, hindlimb paresis (due to thromboembolism), and lethargy. Acute onset of AF with a rapid ventricular response can lead to hemodynamic collapse and cardiogenic shock. Chronic AF may result in progressive myocardial dysfunction and worsening heart failure.

Differential diagnoses for an irregularly irregular rhythm include: 1) Atrial premature complexes (APCs) with variable conduction, which are usually less chaotic and may have a pattern. 2) Multifocal atrial tachycardia, which is rare in animals. 3) Atrial flutter with variable AV block, which may show a sawtooth pattern on ECG. 4) Sinus arrhythmia with wandering pacemaker, which is a normal variant in dogs and is rate-dependent. 5) Ventricular premature complexes (VPCs) with irregular rhythm, but these are typically not as irregular and may have a pulse deficit. 6) Sick sinus syndrome, which can cause bradyarrhythmias and tachyarrhythmias, but the rhythm is often not as irregular. 7) Hyperthyroidism in cats, which can cause sinus tachycardia or AF. 8) Electrolyte disturbances, such as hypokalemia, can cause arrhythmias. Definitive diagnosis is made via electrocardiography (ECG), which shows absence of P waves, fibrillatory waves, and irregular R-R intervals.

The diagnostic approach to atrial fibrillation begins with a thorough history and physical examination, with emphasis on cardiac auscultation and pulse assessment. If AF is suspected, the following steps are recommended: 1) Electrocardiography (ECG) is the gold standard for diagnosis, confirming the absence of P waves, presence of fibrillatory waves, and irregularly irregular R-R intervals. A baseline ECG also assesses ventricular rate and identifies concurrent arrhythmias. 2) Thoracic radiographs are essential to evaluate cardiac size, pulmonary vasculature, and evidence of congestive heart failure (e.g., pulmonary edema, pleural effusion). 3) Echocardiography is crucial to identify underlying structural heart disease, measure atrial dimensions, assess ventricular function, and rule out thrombi. 4) Blood pressure measurement to detect hypertension. 5) Complete blood count, serum biochemistry, and thyroid hormone levels (especially in cats) to rule out systemic causes. 6) Cardiac biomarkers such as NT-proBNP and troponin I may be helpful in assessing myocardial stress and injury. 7) In cases of suspected myocarditis, cardiac troponin and inflammatory markers may be measured. 8) Holter monitoring (24-hour ambulatory ECG) may be indicated to assess the burden of AF and ventricular rate control over time, especially in asymptomatic cases.

Laboratory findings in atrial fibrillation are often nonspecific but may reflect underlying disease. Complete blood count may show stress leukogram or evidence of infection if myocarditis is present. Serum biochemistry may reveal electrolyte imbalances, particularly hypokalemia or hypomagnesemia, which can exacerbate arrhythmias. In dogs with congestive heart failure, liver enzymes (ALT, ALP) may be mildly elevated due to hepatic congestion. Renal parameters (BUN, creatinine) may be abnormal if cardiac output is severely compromised. Thyroid hormone levels (total T4, free T4) are essential in cats to rule out hyperthyroidism. Cardiac biomarkers: NT-proBNP is often elevated in dogs and cats with cardiac disease and may be used to differentiate cardiac from non-cardiac causes of respiratory signs. Troponin I may be elevated in cases of myocardial injury. In horses, AF is often associated with no laboratory abnormalities. In general, laboratory testing is more useful for identifying secondary causes than for diagnosing AF itself.

Imaging plays a critical role in the evaluation of atrial fibrillation. Thoracic radiography typically shows cardiomegaly, with left atrial enlargement evident as a bulge in the caudodorsal cardiac silhouette on the lateral view. Pulmonary venous congestion and interstitial or alveolar pulmonary edema may be present in cases of congestive heart failure. In dogs with DCM, generalized cardiomegaly and pulmonary edema are common. Echocardiography is the most valuable imaging modality, providing detailed assessment of cardiac structure and function. In AF, echocardiography reveals atrial enlargement, which may be severe. Left ventricular dimensions and systolic function (ejection fraction, fractional shortening) are assessed to identify DCM. Valvular morphology and function are evaluated for degenerative changes. Doppler echocardiography can assess diastolic function and estimate pulmonary artery pressure. In cats, echocardiography is essential to diagnose hypertrophic cardiomyopathy, which often shows concentric left ventricular hypertrophy and left atrial enlargement. Transesophageal echocardiography is rarely used in veterinary patients but may be employed to rule out atrial thrombi before cardioversion. Advanced imaging such as CT or MRI is not routinely indicated but may be used for research or complex cases.

Cytology and histopathology are not typically used in the diagnosis of atrial fibrillation, as the arrhythmia is diagnosed by ECG. However, if an underlying myocardial disease is suspected, endomyocardial biopsy may be performed, though it is rarely indicated in clinical practice. Histopathological findings in dogs with AF secondary to DCM include myocyte degeneration, fibrosis, and fatty infiltration. In chronic valvular disease, histopathology shows myxomatous degeneration of the mitral valve leaflets. In cats with hypertrophic cardiomyopathy, histopathology reveals myocyte hypertrophy, disarray, and interstitial fibrosis. In cases of myocarditis, inflammatory infiltrates (lymphocytes, neutrophils) are seen. These findings are more relevant for research or post-mortem diagnosis than for antemortem clinical management.

The treatment of atrial fibrillation in veterinary patients focuses on controlling the ventricular rate, managing underlying heart disease, and addressing congestive heart failure if present. The primary goals are to improve clinical signs and quality of life, not necessarily to restore sinus rhythm. Rate control is achieved with drugs that slow AV nodal conduction. The most commonly used agents are digoxin and diltiazem. Digoxin is a positive inotrope and negative chronotrope, but its effect on rate control is modest and it has a narrow therapeutic index. Diltiazem, a calcium channel blocker, is more effective for rate control and is often preferred. In emergency situations with rapid ventricular rates and hemodynamic instability, intravenous diltiazem or esmolol (a beta-blocker) may be used. Beta-blockers such as atenolol or propranolol can also be used for rate control, especially in cats. In cases of congestive heart failure, diuretics (furosemide), ACE inhibitors (enalapril, benazepril), and pimobendan are indicated. Electrical cardioversion is rarely performed in veterinary medicine due to the high recurrence rate and the need for general anesthesia, but it may be considered in cases of lone AF with refractory clinical signs. In cats, treatment of the underlying cause (e.g., hyperthyroidism) may resolve AF. Anticoagulant therapy is not routinely recommended in dogs and cats due to the low risk of thromboembolism, but it may be considered in cats with severe atrial enlargement and previous thromboembolism.

The prognosis for atrial fibrillation depends on the underlying cause and the success of rate control. In dogs with lone AF and no structural heart disease, the prognosis is generally good, with many dogs living for years with appropriate rate control. However, the arrhythmia is often progressive, and some dogs may develop tachycardia-induced cardiomyopathy if the ventricular rate is not adequately controlled. In dogs with AF secondary to DCM or chronic valvular disease, the prognosis is more guarded, as these conditions are progressive. The median survival time for dogs with AF and DCM is approximately 6-12 months, while dogs with AF and mitral valve disease may survive 1-2 years. Poor prognostic indicators include severe atrial enlargement, poor ventricular function, and failure to achieve adequate rate control. In cats, AF is often a marker of severe cardiac disease, and the prognosis is poor, with a median survival time of less than 6 months. The presence of congestive heart failure at the time of diagnosis significantly worsens the prognosis.

Follow-up for atrial fibrillation involves regular re-evaluations to assess clinical signs, ventricular rate control, and progression of underlying heart disease. Initially, re-evaluation should occur 1-2 weeks after initiating or adjusting rate control medications. At each visit, a physical examination, ECG, and blood pressure measurement should be performed. Serum digoxin levels should be monitored if digoxin is used, with therapeutic range typically 0.8-2.0 ng/mL in dogs. Electrolytes and renal function should be checked periodically, especially if diuretics are used. Echocardiography should be repeated every 6-12 months to monitor cardiac remodeling and function. Holter monitoring may be recommended to assess the average ventricular rate over 24 hours, aiming for a rate of <150 bpm in dogs and <140 bpm in cats. Owners should be educated to monitor resting respiratory rate and heart rate at home, and to seek immediate veterinary care if signs of heart failure worsen. Long-term management includes ongoing therapy for underlying heart disease and adjustments of antiarrhythmic drugs as needed.

Pearls: 1) Always auscultate for an irregularly irregular rhythm and check for pulse deficits; this is a hallmark of AF. 2) In large-breed dogs with AF, always rule out DCM with echocardiography, even if the dog appears otherwise healthy. 3) Diltiazem is often more effective than digoxin for rate control and has fewer side effects. 4) In cats, AF is almost always secondary to significant cardiac disease; treat the underlying cause. 5) Use ECG to confirm the diagnosis; do not rely solely on auscultation. Pitfalls: 1) Do not attempt to cardiovert AF to sinus rhythm without addressing the underlying cause; recurrence is likely. 2) Avoid using digoxin as the sole rate control agent in dogs with rapid ventricular rates; it may be insufficient. 3) Do not ignore electrolyte imbalances, as they can exacerbate AF. 4) Be cautious with beta-blockers in patients with congestive heart failure, as they can worsen myocardial function. 5) Do not forget to monitor digoxin levels to avoid toxicity, which can cause life-threatening arrhythmias.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are recommended for atrial fibrillation in dogs and cats: 1) Diltiazem: Dogs: 0.5-1.5 mg/kg PO q8h, or sustained-release 3-5 mg/kg PO q12h; for emergency rate control, IV bolus 0.25 mg/kg over 2-3 minutes, followed by CRI at 2-6 mcg/kg/min. Cats: 1-2.5 mg/kg PO q8h, or sustained-release 10 mg/kg PO q12h; IV dose 0.25 mg/kg over 2-3 minutes, then CRI 2-6 mcg/kg/min. 2) Digoxin: Dogs: 0.005-0.01 mg/kg PO q12h (max 0.25 mg/dog); Cats: 0.007-0.01 mg/kg PO q48h (max 0.125 mg/cat). Monitor serum levels. 3) Atenolol: Dogs: 0.25-1 mg/kg PO q12h; Cats: 6.25-12.5 mg/cat PO q12h. 4) Esmolol (IV only): Dogs: 50-200 mcg/kg/min CRI after a 0.5 mg/kg loading dose over 1 minute. 5) Furosemide: Dogs: 1-4 mg/kg IV, IM, SC, or PO q8-12h; Cats: 1-2 mg/kg IV, IM, SC, or PO q12-24h. 6) Enalapril: Dogs: 0.5 mg/kg PO q12h; Cats: 0.25-0.5 mg/kg PO q12h. 7) Pimobendan: Dogs: 0.25-0.3 mg/kg PO q12h; Cats: 1.25 mg/cat PO q12h. 8) For cats with hyperthyroidism, methimazole 2.5-5 mg/cat PO q12h. Adjust dosages in renal or hepatic impairment. Avoid concurrent use of diltiazem and beta-blockers due to risk of severe bradycardia.

Evidence-based literature on atrial fibrillation in veterinary medicine is limited but growing. A landmark study by Bonagura et al. (1991) evaluated the use of diltiazem for rate control in dogs with AF, demonstrating significant reduction in ventricular rate with minimal side effects. A more recent study by Pedro et al. (2017) compared digoxin and diltiazem for rate control in dogs with AF and found diltiazem to be superior in achieving target heart rates. The ACVIM consensus statement on the diagnosis and treatment of canine chronic valvular heart disease (2019) recommends rate control for AF, with diltiazem as a first-line agent. In cats, a study by Smith et al. (2003) reported that AF is rare but associated with poor prognosis. The use of pimobendan in dogs with DCM and AF was evaluated in the EPIC study (2016), which showed improved survival in dogs with DCM, though AF was not a primary endpoint. Overall, there is a lack of randomized controlled trials, and most recommendations are based on expert opinion and extrapolation from human medicine. Future research should focus on optimal rate control targets and the role of anticoagulation in veterinary patients.